Medline $MDLN Shares Sold by Machina Capital S.A.S.

Machina Capital S.A.S. decreased its stake in Medline (NASDAQ:MDLN – Free Report) by 46.9% in the third quarter, Holdings Channel.com reports. The firm owned 14,677 shares of the company’s stock after selling 12,986 shares during the period. Machina Capital S.A.S.’s holdings in Medline were worth $509,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of MDLN. MFF Capital Investments Ltd bought a new position in Medline during the 3rd quarter valued at about $3,470,000. Montaka Global Pty Ltd purchased a new position in shares of Medline during the third quarter valued at approximately $3,123,000. Fulcrum Asset Management LLP bought a new position in shares of Medline during the third quarter valued at approximately $445,000. Allspring Global Investments Holdings LLC raised its holdings in shares of Medline by 30,255.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after buying an additional 2,691,529 shares during the period. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Medline by 21.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 215,114 shares of the company’s stock worth $7,464,000 after acquiring an additional 37,928 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Wall Street Zen upgraded Medline from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. TD Cowen decreased their target price on Medline from $53.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Robert W. Baird set a $42.00 target price on shares of Medline in a research note on Thursday, August 6th. Leerink Partners boosted their target price on shares of Medline from $43.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, Tigress Financial cut their price target on shares of Medline from $62.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Twenty-three research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Medline has an average rating of “Moderate Buy” and an average target price of $46.08.

Check Out Our Latest Report on Medline

Insider Activity

In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of the business’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the sale, the insider owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. The trade was a 11.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 6,348,676 shares of company stock valued at $224,525,137. 0.81% of the stock is owned by corporate insiders.

Medline Price Performance

MDLN opened at $39.47 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.04 and a quick ratio of 2.51. The firm has a market capitalization of $51.92 billion and a PE ratio of 89.71. The business’s 50-day moving average is $35.28 and its two-hundred day moving average is $39.37. Medline has a 1 year low of $31.37 and a 1 year high of $50.88.

Medline (NASDAQ:MDLN – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.32 by $0.12. Medline had a return on equity of 8.21% and a net margin of 1.84%. The firm had revenue of $7.86 billion during the quarter. Research analysts anticipate that Medline will post 1.58 earnings per share for the current fiscal year.

Medline Profile

(Free Report)

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.

See Also

Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN – Free Report).

Institutional Ownership by Quarter for Medline (NASDAQ:MDLN)

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.